IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Immunic, Inc. (IMUX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D). The rating has held at C for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B+ (3.7) | C (2.4) | D+ (1.6) | D (1.3) | C+ (2.6) | C (2.3) |
| 2026-11-05 | A- (3.9) | C (2.4) | D+ (1.6) | D+ (1.6) | C+ (2.7) | C (2.4) |
| 2026-10-29 | B+ (3.7) | C (2.4) | D+ (1.6) | C- (1.9) | C+ (2.7) | C (2.4) |
| 2026-10-22 | B+ (3.7) | C (2.3) | D+ (1.6) | C (2.4) | C+ (2.6) | C+ (2.5) |
| 2026-10-15 | B+ (3.7) | C (2.3) | D+ (1.6) | C- (1.9) | C+ (2.6) | C (2.4) |